A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
Tóm tắt
Antibodies against cyclic citrullinated peptide (CCP) and rheumatoid factors (RFs) have been demonstrated to predate the onset of rheumatoid arthritis (RA) by years. A nested case–control study was performed within the Northern Sweden Health and Disease study cohort to analyse the presence of shared epitope (SE) genes, defined as HLA-DRB1*0404 or DRB1*0401, and of anti-CCP antibodies and RFs in individuals who subsequently developed RA. Patients with RA were identified from among blood donors whose samples had been collected years before the onset of symptoms. Controls matched for age, sex, and date of sampling were selected randomly from the same cohort. The SE genes were identified by polymerase chain reaction sequence-specific primers. Anti-CCP2 antibodies and RFs were determined using enzyme immunoassays. Fifty-nine individuals with RA were identified as blood donors, with a median antedating time of 2.0 years (interquartile range 0.9–3.9 years) before presenting with symptoms of RA. The sensitivity for SE as a diagnostic indicator for RA was 60% and the specificity was 64%. The corresponding figures for anti-CCP antibodies were 37% and 98%, and for RFs, 17–42% and 94%, respectively. In a logistic regression analysis, SE (odds ratio [OR] = 2.35), anti-CCP antibodies (OR = 15.9), and IgA-RF (OR = 6.8) significantly predicted RA. In a combination model analysis, anti-CCP antibodies combined with SE had the highest OR (66.8, 95% confidence interval 8.3–539.4) in predicting RA, compared with anti-CCP antibodies without SE (OR = 25.01, 95% confidence interval 2.8–222.2) or SE without anti-CCP antibodies (OR = 1.9, 95% confidence interval 0.9–4.2). This study showed that the presence of anti-CCP antibodies together with SE gene carriage is associated with a very high relative risk for future development of RA.
Tài liệu tham khảo
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.
Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT: When does rheumatoid disease start?. Arthritis Rheum. 1985, 28: 485-489.
Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide (CCP) and immunoglobulin-A rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 10: 2741-2749. 10.1002/art.11223.
Jawaheer D, Gregersen PK: Rheumatoid arthritis. The genetic components. Rheum Dis Clin North Am. 2002, 28: 1-15. 10.1016/S0889-857X(03)00066-8.
Rantapää Dahlqvist S: Genetic markers in rheumatoid arthritis. Scand J Rheumatol. 1986, Suppl 58: 1-29.
Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E: Cutting edge: The conversion of ariginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC classII molecule. J Immunol. 2003, 171: 538-541.
Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Menard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR, El-Gabalawy HS: Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000, 2: 236-243. 10.1186/ar93.
Bas S, Genevay S, Meyer O, Gabay C: Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology. 2003, 42: 677-680. 10.1093/rheumatology/keg184.
Zanelli E, Breedveld FC, Vries de RRP: HLA association with autoimmune disease: a failure to protect?. Rheumatology. 2000, 39: 1060-1066. 10.1093/rheumatology/39.10.1060.
Wernhoff P, Olofsson P, Holmdahl R: The genetic control of rheumatoid factor production in a rat model of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 3584-3596. 10.1002/art.11342.
Gorman JD, Criswell LA: The shared epitope and severity of rheumatoid arthritis. Rheum Dis Clin North Am. 2002, 28: 59-78. 10.1016/S0889-857X(03)00069-3.
Deighton CM, Walker DJ, Griffiths ID, Roberts DF: The contribution of HLA to rheumatoid arthritis. Clin Genet. 1989, 36: 178-182.
Rigby AS, Silman AJ, Voelm L, Gregory JC, Ollier WE, Khan MA, Nepom GT, Thomson G: Investigating the HLA component in rheumatoid arthritis: an additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet Epidemiol. 1991, 8: 153-175.
Rigby AS, Voelm L, Silman AJ: Epistatic modeling in rheumatoid arthritis: an application of the Risch theory. Genet Epidemiol. 1993, 10: 311-320.
Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K: Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003, 34: 395-402. 10.1038/ng1206.
Caponi L, Petit-Teixeira E, Sebbag M, Bongiorni F, Moscato S, Pratesi F, Osorio J, Guerrin-Weber M, Cornelis F, Serre G, Migliorini P: Analysis of the peptidylarginine deiminase V gene in rheumatoid arthritis [abstract]. Arthritis Res. 2003, Suppl 5: 1-